Tasmania's iconic devils are facing an existential threat in the form of a deadly facial cancer, but a glimmer of hope has emerged through a groundbreaking research collaboration. This partnership, between the Colossal Foundation and the University of Tasmania, aims to harness the power of gene editing to combat the devastating DFTD (devil facial tumour disease).
The Battle Against Extinction
DFTD has already claimed the lives of approximately 80% of wild Tasmanian devils since its emergence in 1996. The disease spreads rapidly through biting during feeding and mating, leading to tumours that ultimately prevent the animals from eating and result in a near-certain death. The situation is dire, with two distinct cancers, DFT1 and DFT2, further complicating matters.
A Two-Pronged Approach to Survival
The research team is adopting a dual strategy. Firstly, they are developing an oral bait vaccine, a potentially game-changing innovation that could train the devil immune system to fight both cancers. The vaccine, if successful, could protect wild devils across Tasmania without the need for individual trapping and injection. This approach is made possible by the Colossal Foundation's support, which will also fund the establishment of a colony of fat-tailed dunnarts for pre-trial testing.
Andrew Flies, leading the vaccine development at the Menzies Institute for Medical Research, emphasizes the challenges of working with an endangered species and the lack of marsupial research tools. He believes that partnering with the Colossal Foundation will accelerate their progress and enable them to explore gene-editing strategies simultaneously.
The second approach targets the LZTR1 gene, which researchers suspect plays a role in the origin of the tumours. By editing this gene, they aim to reduce the devils' susceptibility to the cancers.
Ecosystem Implications
The decline of Tasmanian devils has broader ecological consequences. As the apex scavenger of Tasmania, their absence has allowed feral cats to spread, disrupting the delicate balance of the ecosystem. The research partnership's efforts are not just about saving a species but also about preserving the integrity of Tasmania's natural environment.
Applying Lessons from the Past
The Colossal Foundation's expertise in marsupial research stems from their ambitious project to bring back the thylacine, commonly known as the Tasmanian tiger. Now, they are leveraging these tools to benefit living species, showcasing the potential for innovative conservation strategies.
A Race Against Time
While the vaccine shows promise, it must first undergo safety trials before it can be tested on wild devils. This process underscores the urgency of the situation and the need for rapid progress. The fate of the Tasmanian devils hangs in the balance, and the world watches with bated breath, hoping that this innovative approach will turn the tide in their favor.
In my opinion, this story highlights the incredible potential of scientific collaboration and the power of gene editing to address complex conservation challenges. It's a testament to human ingenuity and our ability to adapt and find solutions, even in the face of seemingly insurmountable odds.
